Michael Gold

Chief R&D Officer

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Gold is the Chief R&D Officer at Compass Pathways in the United Kingdom. His research areas focus on multiple sclerosis, major depressive disorder, and Alzheimer's disease, as evidenced by his recent publications on efficacy and safety studies of novel therapeutics and the exploration of biomarkers. He has contributed to various clinical trials and systematic reviews aimed at enhancing treatment strategies and understanding clinical challenges in neurology.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Boccardi Marina

Prof.

Universitätsmedizin Rostock

GERMANY

View details

Jean-Pierre Brion

Director of LHNN, Professor

Université libre de Bruxelles

BELGIUM

View details

Julie M. Robillard

CANADA

View details

Diana Kerwin

University of Texas Southwestern Medical Center

UNITED STATES

View details

Brian Willis

Head of Pharmacometrics

Biogen Idec

UNITED STATES

View details

Bruce Cree

Professor of Clinical Neurology

University of California, San Francisco

UNITED STATES

View details

Andrea Mothe

Krembil Research Institute

CANADA

View details

Kaycee Sink

Chief Medical Officer

Cogstate, Inc

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Gold

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis

Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial.

Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation.

Facilitating the use of the target product profile in academic research: a systematic review

Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease.

Why should academia care about the Target Product Profile?

Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion

Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.

Clinical research in dementia: A perspective on implementing innovation

Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.

Current directions in tau research: Highlights from Tau 2020

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Building clinically relevant outcomes across the Alzheimer's disease spectrum

Hippocampal Neuroimaging‐Informed Clinical Trial Enrichment Tool for Amnestic Mild Cognitive Impairment Using Open Data

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Collaborators (8)

Boccardi Marina

Jean-Pierre Brion

Julie M. Robillard

Diana Kerwin

Brian Willis

Bruce Cree

Andrea Mothe

Kaycee Sink

Make your next move.